Review
Oncology
Craig T. Wallington-Beddoe, Rachel L. Mynott
Summary: New approaches are needed to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, however, insufficient information currently exists to utilize biomarkers to tweak treatment. With the increasing complexity of drug classes used to treat multiple myeloma, clinically useful biomarkers are crucial in guiding personalized patient management.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Sandra Pavicevic, Sophie Reichelt, Deniz Uluk, Isabella Lurje, Cornelius Engelmann, Dominik P. Modest, Uwe Pelzer, Felix Krenzien, Nathanael Raschzok, Christian Benzing, Igor M. Sauer, Sebastian Stintzing, Frank Tacke, Wenzel Schoening, Moritz Schmelzle, Johann Pratschke, Georg Lurje
Summary: Cholangiocarcinoma is a rapidly increasing global malignancy of the biliary tract, often presenting with advanced or unresectable disease. Biomarkers obtained from patients' serum or tumor tissue could help guide therapy and identify those at higher risk of recurrence. Genetic aberrations in cholangiocarcinoma have also been linked with improved response to targeted therapies. This review provides an overview of prognostic and predictive biomarkers in cholangiocarcinoma.
Article
Oncology
Shunsuke Fukui, Kohei Ikeda, Mayu Kobayashi, Keigo Nishida, Keita Yamada, Shotaro Horie, Yasuaki Shimada, Hiroto Miki, Hiroki Goto, Koken Hayashi, Yuuichi Nakazawa, Hiroki Mizutani, Toshitaka Kamon, Yusuke Tanigaito, Shuji Kodama, Takashi Kato, Yuuki Nishiura, Daisuke Suga, Toshikazu Terashima, Yuhuko Ichikawa, Isao Moritani, Akitaka Yamamoto, Kei Takaba, Kouji Yasumoto, Hideo Wada, Katsuya Shiraki
Summary: The present study aimed to identify useful biomarkers to predict deterioration in patients with COVID-19. Several blood markers, including CRP, PSP, LDH, and AST, were found to be reliable indicators for predicting the prognosis of non-severe cases. However, no blood biomarkers were able to predict the outcome in severe cases.
MOLECULAR MEDICINE REPORTS
(2023)
Review
Oncology
Yi-Chih Tsai, Min-Chieh Hsin, Rui-Jun Liu, Ting-Wei Li, Hui-Ju Ch'ang
Summary: Pancreatic adenocarcinoma (PDAC) has poor prognosis and radiotherapy does not provide survival benefits compared to systemic chemotherapy. Early distant metastasis is common in localized PDAC, thus upfront chemotherapy has been suggested. Tissue biomarkers such as SMAD4 and Kruppel-like factor 10 (KLF10) have been identified to predict the efficacy and survival benefits of radiotherapy for localized PDAC. The combination of KLF10 and SMAD4 expression may help select patients who may benefit the most from additional radiotherapy.
Review
Cell Biology
Oluwaseyi Adeuyan, Emily R. Gordon, Divya Kenchappa, Yadriel Bracero, Ajay Singh, Gerardo Espinoza, Larisa J. Geskin, Yvonne M. Saenger
Summary: The approval of immunotherapy for stage II-IV melanoma has highlighted the need for improved immune-based predictive and prognostic biomarkers. Several techniques are currently under investigation for the detection of prognostic and predictive immune biomarkers in melanoma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Oncology
Qifeng Wang, Lin Peng, Yongtao Han, Tao Li, Wei Dai, Yi Wang, Lei Wu, Yang Wei, Tianpeng Xie, Qiang Fang, Qiang Li, Jinyi Lang, Bangrong Cao
Summary: Low preoperative serum sodium is associated with poor outcome in esophageal carcinoma patients, and may predict survival benefit of adjuvant therapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Paulina Sledzinska, Marek G. Bebyn, Jacek Furtak, Janusz Kowalewski, Marzena A. Lewandowska
Summary: The latest research on prognostic and predictive biomarkers in gliomas has been compiled, highlighting the importance of prognostic markers in adult and pediatric patients and the clinical significance in predicting treatment responses. Further work is needed to implement novel technologies such as liquid biopsies in clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Health Care Sciences & Services
Maja Sutic, Ana Vukic, Jurica Baranasic, Asta Foersti, Feda Dzubur, Miroslav Samarzija, Marko Jakopovic, Luka Brcic, Jelena Knezevic
Summary: Lung cancer is the leading cause of cancer-related deaths globally, with most patients still being diagnosed at an advanced stage despite screening efforts for high-risk populations. In the past decade, management of lung cancer has significantly progressed towards personalized treatments, with molecular biomarkers playing a crucial role in prognosis and predicting therapy response. Non-small cell lung cancer, being the most common type, is the primary focus for discussion on promising new biomarkers in clinical management.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Katharina Doetzer, Friederike Schlueter, Franz Edler von Koch, Christine E. Brambs, Sabine Anthuber, Sergio Frangini, Bastian Czogalla, Alexander Burges, Jens Werner, Sven Mahner, Barbara Mayer
Summary: Integrin alpha 2 beta 1 has been identified as a prognostic and predictive marker in primary ovarian cancer, showing significant correlations with ERα, EGFR, immune cell infiltration, and PD-L1 expression. High alpha 2 beta 1 expression is associated with shorter survival, serving as an independent prognostic factor for patients' progression-free and platinum-free intervals. It has the potential to stratify patients for chemotherapy and immunotherapy and design new targeted treatment strategies.
Review
Oncology
Benjamin Verret, Michele Bottosso, Sofia Hervais, Barbara Pistilli
Summary: This article reviews the knowledge about predictive and prognosis biomarkers in metastatic breast cancer based on molecular profiling studies. It summarizes the findings of important studies deciphering the molecular landscape of metastatic breast cancer and identifies molecular alterations associated with treatment response or resistance. The article also classifies the validated and emergent molecular biomarkers in metastatic breast cancer according to the level of evidence and ESCAT classification, and provides perspective on their development in clinical practice.
Review
Health Care Sciences & Services
Michal Szczyrek, Paulina Bitkowska, Marta Jutrzenka, Janusz Milanowski
Summary: Lung cancer, a leading cause of global cancer-related deaths, is often diagnosed at advanced stages due to limited diagnostic possibilities. However, the use of miRNAs as diagnostic, predictive, and prognostic markers in non-small-cell lung cancer (NSCLC) has gained attention in recent years. Abnormal expression levels of miRNAs can detect NSCLC in its early asymptomatic stages, potentially improving clinical outcomes and serving as predictive factors for NSCLC treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Oncology
Siddhartha Deb, Anannya Chakrabarti, Stephen B. Fox
Summary: The importance of identifying and targeting in treating familial breast cancers is recognized. This review paper focuses on prognostic and predictive tumour biomarkers within familial breast cancer. These cancers are different from sporadic cases, with earlier age of onset and specific breast cancer subtypes. However, there is limited research on relevant prognostic and predictive biomarkers within this breast cancer subgroup.
Article
Gastroenterology & Hepatology
Ke Su, Yanlin Liu, Pan Wang, Kun He, Fei Wang, Hao Chi, Mingyue Rao, Xueting Li, Lianbin Wen, Yanqiong Song, Jianwen Zhang, Tao Gu, Ke Xu, Qi Li, Jiali Chen, Zhenying Wu, Han Li, Weihong Huang, Lan Chen, Jian Tong, Hongyan Li, Xunjie Feng, Siyu Chen, Binbin Yang, Hongping Jin, Yue Yang, Hanlin Liu, Chao Yang, Ming Wu, Fangyu Xiong, Keyi Peng, Lechuan Zhu, Yaoyang Xu, Xue Tang, Zunyuan Tan, Xiaotong Luo, Hanyue Zheng, Yuxin Zhang, Lu Guo, Yunwei Han
Summary: Our study confirmed that plasma HSP90 alpha level can be used as a prognostic biomarker for HCC.
HEPATOLOGY INTERNATIONAL
(2022)
Review
Biochemistry & Molecular Biology
Qasem Al-Tashi, Maliazurina B. Saad, Amgad Muneer, Rizwan Qureshi, Seyedali Mirjalili, Ajay Sheshadri, Xiuning Le, Natalie I. Vokes, Jianjun Zhang, Jia Wu
Summary: The identification of biomarkers is crucial in personalized medicine, but differentiating between predictive and prognostic biomarkers can be challenging due to overlap. Prognostic biomarkers predict cancer outcomes regardless of treatment, while predictive biomarkers assess the effectiveness of therapeutic interventions. Misclassifying them can have serious consequences for patients. This study provides an in-depth analysis of recent advancements, challenges, and future prospects in biomarker identification, using a systematic search of studies published between 2017 and 2023. The review aims to serve as a valuable resource for researchers in understanding biomarker discovery methods and identifying future research opportunities.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
R. Varaljai, S. Elouali, S. S. Lueong, K. Wistuba-Hamprecht, T. Seremet, J. T. Siveke, J. C. Becker, A. Sucker, A. Paschen, P. A. Horn, B. Neyns, B. Weide, D. Schadendorf, A. Roesch
Summary: This study demonstrates that high cfDNA concentration can serve as a biomarker for melanoma regardless of tumor genotype, providing information on tumor burden, risk of progression, and risk of death.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Oncology
Matthew R. Smith, Howard Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N. Chi, Fred Saad, Olof Stahl, David Olmos, Daniel C. Danila, Gary E. Mason, Byron M. Espina, Xin Zhao, Karen A. Urtishak, Peter Francis, Angela Lopez-Gitlitz, Karim Fizazi
Summary: This study evaluated the anti-tumor activity and safety of niraparib, a PARP inhibitor, in patients with metastatic castration-resistant prostate cancers and DNA repair gene defects (DRDs) who had previously failed treatment with an androgen signaling inhibitor and a taxane. The results showed that niraparib was well-tolerated and demonstrated anti-tumor activity in these patients, particularly in those with BRCA alterations.
Review
Oncology
Annika Fendler, Elisabeth G. E. de Vries, Corine H. GeurtsvanKessel, John B. Haanen, Bernhard Wormann, Samra Turajlic, Marie von Lilienfeld-Toal
Summary: The efficacy and immunogenicity of COVID-19 vaccines in cancer patients are uncertain due to their exclusion from pivotal clinical trials. In this Review, the current knowledge on vaccine efficacy and immune responses in cancer patients is summarized, highlighting key factors that may affect vaccine efficacy in this population.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Danique Giesen, Marjolijn N. Lub-de Hooge, Marcel Nijland, Helen Heyerdahl, Jostein Dahle, Elisabeth G. E. de Vries, Martin Pool
Summary: In this study, [Lu-177]Lu-DOTA-NNV003 was developed as a novel radioimmunotherapy (RIT) for B cell non-Hodgkin's lymphoma (NHL) patients. The use of [Zr-89]Zr-N-sucDf-NNV003 PET imaging accurately predicted the whole-body distribution and tumor uptake of [Lu-177]Lu-DOTA-NNV003. The results showed that [Zr-89]Zr-N-sucDf-NNV003 PET imaging could serve as a useful tool to predict the CD37-targeting effect of [Lu-177]Lu-DOTA-NNV003.
SCIENTIFIC REPORTS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ananthi Somasundaram, David Vallez Garcia, Elisabeth Pfaehler, Yvonne W. S. Jauw, Josee M. Zijlstra, Guus A. M. S. van Dongen, Willemien C. Menke-van der Houven Van Oordt, Marc C. Huisman, Elisabeth G. E. de Vries, Ronald Boellaard
Summary: This study investigates the impact of noise on radiomic features from Zr-89-Immuno-PET clinical images. It identifies features that are less affected by noise and can serve as potential prognostic and predictive biomarkers in Zr-89-Immuno-PET studies.
Article
Oncology
H. Boery, S. Lubberts, S. Bunskoek, J. Nuver, J. D. Lefrandt, G. Steursma, W. J. Sluiter, S. Siesling, A. J. Berendsen, J. A. Gietema
Summary: Shared-care follow-up is safe and feasible for patients with testicular cancer, allowing personalized care and involvement of primary care physicians in cardiovascular risk management and psychosocial survivorship issues.
Article
Oncology
Willeke R. Naaktgeboren, Wim G. Groen, Judy N. Jacobse, Lars C. Steggink, Annemiek M. E. Walenkamp, Wim H. van Harten, Martijn M. Stuiver, Neil K. Aaronson, Berthe M. P. Aleman, Peter van der Meer, Michael Schaapveld, Gabe S. Sonke, Jourik A. Gietema, Flora E. van Leeuwen, Anne M. May
Summary: Higher levels of physical activity are associated with improved global longitudinal strain (GLS) but not left ventricular ejection fraction (LVEF) in long-term breast cancer survivors. Increasing physical activity may contribute to cardiovascular health benefits, especially in inactive survivors.
JACC: CARDIOONCOLOGY
(2022)
Article
Oncology
Chiara Grasso, Maja Popovic, Elena Isaevska, Fulvio Lazzarato, Valentina Fiano, Daniela Zugna, John Pluta, Benita Weathers, Kurt D'Andrea, Kristian Almstrup, Lynn Anson-Cartwright, D. Timothy Bishop, Stephen J. Chanock, Chu Chen, Victoria K. Cortessis, Marlene D. Dalgaard, Siamak Daneshmand, Alberto Ferlin, Carlo Foresta, Megan N. Frone, Marija Gamulin, Jourik A. Gietema, Mark H. Greene, Tom Grotmol, Robert J. Hamilton, Trine B. Haugen, Russ Hauser, Robert Karlsson, Lambertus A. Kiemeney, Davor Lessel, Patrizia Lista, Ragnhild A. Lothe, Chey Loveday, Coby Meijer, Kevin T. Nead, Jeremie Nsengimana, Rolf I. Skotheim, Clare Turnbull, David J. Vaughn, Fredrik Wiklund, Tongzhang Zheng, Andrea Zitella, Stephen M. Schwartz, Katherine A. McGlynn, Peter A. Kanetsky, Katherine L. Nathanson, Lorenzo Richiardi
Summary: This study found that genetic variants within the MTHFR gene are associated with the risk of testicular germ cell tumors (TGCT), potentially affecting the establishment of DNA methylation patterns. This finding suggests that the pathogenesis of TGCT may be related to the status of the folate cycle, and this relation could be partly due to hereditary factors.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries
Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.
CLINICAL CANCER RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joyce van Sluis, Walter Noordzij, Elisabeth G. E. de Vries, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard
Summary: This study explores the influence of using manual segmentations versus an AI-based automated segmentation tool on calculating whole-body effective doses. The results show that using AI-based segmentations can save time and achieve higher similarity coefficients compared to manual segmentations. The whole-body effective doses show minimal differences for the six patients.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Article
Oncology
S. F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N. J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E. G. E. de Vries, M. Piccart, N. I. Cherny
Summary: This article discusses the importance of quality of life (QoL) data and quality assurance measures in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Through field testing and revision, a checklist consisting of four items was developed to ensure the reliability and clinical relevance of QoL data. Implementation of this checklist will facilitate objective and transparent decision making in the ESMO-MCBS scoring process.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Andor W. J. M. Glaudemans, Philippe Aftimos, Geraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt
Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H. J. T. de Hingh, Frank J. P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G. E. de Vries, Carin A. Uyl-de Groot, Sabine Siesling
Summary: This study evaluated the changes in survival of patients with de novo metastatic solid cancers over the past 30 years. The proportion of M1 disease and net survival rates varied among different cancer types. Better preventive measures and early detection are needed to reduce the incidence of metastatic disease.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Multidisciplinary Sciences
Elena Garralda, Scott A. Laurie, Lesley Seymour, Elisabeth G. E. de Vries
Summary: Early detection of immunotherapy-induced tumor response is crucial, but therapy-induced pseudoprogression can make it complicated. A consensus guideline called iRECIST, a modification of RECIST version 1.1, was developed. This article explores the next steps required to test its validity and proposes novel approaches for response criteria.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale
Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.
Letter
Oncology
Sjoukje Lubberts, Flora E. van Leeuwen, Michael Schaapveld, Jourik A. Gietema
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
